299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05530278
(ClinicalTrials.gov)
September 20, 20225/9/2022A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic FibrosisAssessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of Galicaftor, Navocaftor and ABBV-576 and Potential of ABBV-576 for CYP3A Induction in Healthy VolunteersHealthy VolunteersDrug: Galicaftor;Drug: ABBV-576;Drug: Navocaftor;Drug: MidazolamAbbVieNULLCompleted18 Years65 YearsFemale24Phase 1United States
2NCT04853368
(ClinicalTrials.gov)
September 20, 202119/4/2021Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisA Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del MutationCystic Fibrosis (CF)Drug: ABBV-576;Drug: Galicaftor;Drug: Placebo;Drug: Navocaftor;Drug: ABBV-119AbbVieNULLRecruiting18 YearsN/AAll90Phase 2United States;Australia;Belgium;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;Czechia;Germany